WASHINGTON (AP) -- The makers of the diabetes drug Avandia are disputing the federal government's claims the drug is linked to an increased risk of heart attacks.
A doctor with the Food and Drug Administration today recommended to a daylong conference of experts that Avandia be pulled from the market.
However, officials at GlaxoSmithKline cite their own analyses of studies, calling the data inconsistent. They say the research offers no overall evidence of differences with other antidiabetes drugs when it comes to heart risks.
They're scheduled to spell out their position to the meeting in Washington later today.